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Resveratrol is a cancer preventative agent that is found in red wine. Piceatannol is a closely related stilbene that has antileukaemic
activity and is also a tyrosine kinase inhibitor. Piceatannol differs from resveratrol by having an additional aromatic hydroxy group.
The enzyme CYP1B1 is overexpressed in a wide variety of human tumours and catalyses aromatic hydroxylation reactions. We
report here that the cancer preventative agent resveratrol undergoes metabolism by the cytochrome P450 enzyme CYP1B1 to
give a metabolite which has been identiﬁed as the known antileukaemic agent piceatannol. The metabolite was identiﬁed by high
performance liquid chromatography analysis using ﬂuorescence detection and the identity of the metabolite was further conﬁrmed
by derivatisation followed by gas chromatography–mass spectrometry studies using authentic piceatannol for comparison. This
observation provides a novel explanation for the cancer preventative properties of resveratrol. It demonstrates that a natural
dietary cancer preventative agent can be converted to a compound with known anticancer activity by an enzyme that is found in
human tumours. Importantly this result gives insight into the functional role of CYP1B1 and provides evidence for the concept that
CYP1B1 in tumours may be functioning as a growth suppressor enzyme.
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Resveratrol is a natural product found in red wine, and has been
shown to have cancer preventative properties (Jang et al, 1997; Jang
and Pezzuto, 1999). Resveratrol may be classiﬁed either as a poly-
phenol or as a phytoestrogen, and has the stilbene core structure.
Piceatannol is a closely related phytoestrogen that also has the stil-
bene structure (Figure 1A). Piceatannol has known anticancer
properties and was identiﬁed as the antileukaemic principle
obtained from a plant extract (Ferrigni et al, 1984). Piceatannol
was later found to exhibit potent tyrosine kinase inhibitory activity
(Geahlen and McLaughlin, 1989). Subsequent studies have shown
that it inhibits a variety of tyrosine kinases involved in cell prolif-
eration, including the MAP kinases (Fleming et al, 1995), the
tyrosine kinase involved in tubulin phosphorylation (Peters et al,
1996), kinases that are involved in the phosphorylation of DNA
transcription factors (Su and David, 2000), and various other tyro-
sine kinases which are overexpressed in different types of cancer
(Thakkar et al, 1993). The only difference between the stilbenes
resveratrol and piceatannol is the presence of an extra hydroxy
group in one of the aromatic rings of piceatannol.
The enzyme CYP1B1 belongs to the cytochrome P450 enzyme
family (Spink et al, 1994; Sutter et al, 1994). Interestingly the
CYP1B1 protein is highly expressed in human tumours (McKay
et al, 1995; McFadyen et al, 1999). An immunohistochemical study
has shown that the CYP1B1 protein is found in a wide variety of
tumours of different organs such as brain, breast, colon, lung
and ovary, but the protein was not detected in the corresponding
normal tissues (Murray et al, 1997). Although the functional role
of CYP1B1 is unknown, it is known to have aromatic hydroxyla-
tion activity, and catalyses the conversion of estradiol to 4-
hydroxyestradiol (Spink et al, 1994; Hayes et al, 1996) (Figure 1C).
Resveratrol is classiﬁed as a phytoestrogen because of its similar-
ity to the endogenous oestrogen estradiol. The molecular
relationship between resveratrol and estradiol can be seen by
mapping the molecular structure of resveratrol onto the estradiol
framework as shown in Figure 1B. Because of this relationship
we reasoned that resveratrol may also undergo aromatic hydroxyla-
tion by CYP1B1. Furthermore we rationalised that aromatic
hydroxylation at the position corresponding to that of 4-hydro-
xyestradiol would generate the tyrosine kinase inhibitor
piceatannol. We have used this type of mapping to design novel
CYP1B1 activated tyrosine kinase inhibitor prodrugs for tumour
selective cancer therapy using our concept of aromatic hydroxyla-
tion activation, and these prodrugs are based on the stilbene
structure (Potter et al, 2001). We then realised the similarity in
molecular structure of the anticancer prodrugs we had designed
speciﬁcally for CYP1B1 to the molecular structure of certain natur-
al products that have cancer preventative properties, and in
particular the phytoestrogens such as resveratrol. This then led us
to formulate a hypothesis for the functional role of CYP1B1 as a
tumour suppressor enzyme or ‘rescue enzyme’ wherein CYP1B1
serves to activate certain non-toxic dietary components into growth
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the CYP1B1 enzyme. In this pilot study, we report here that resver-
atrol is indeed metabolised by CYP1B1 to generate the
antileukaemic agent piceatannol.
MATERIALS AND METHODS
Resveratrol and piceatannol were obtained from Sigma-Aldrich.
Human lymphoblast expressed CYP1B1 microsomes were obtained
from Gentest.
CYP1B1 metabolism
Human lymphoblast expressed CYP1B1 microsomes (50 ml) were
pre-incubated for 2 min at 378C with 5 ml of stock 50 mM NADPH
(ﬁnal incubate conc.=1.25 mM). Pre-incubation volumes were made
up to 198 ml with 0.1 M sodium/potassium phosphate buffer,
pH 7.6. The reaction was started by the addition of 2 mlo f
20 mM resveratrol in DMSO (ﬁnal incubate conc.=200 mM). Final
volumes were 200 ml. Incubations were carried out in air in a shak-
ing water bath at 120 oscillations per min for 60 min at 378C. The
incubations were carried out under yellow light to avoid possible
photochemical side-reactions. The reaction was stopped after
60 min incubation by adding 105 ml of an ice cold mixture of
methanol (100 ml) and glacial acetic acid (5 ml) followed by placing
on ice. The resulting mixture was centrifuged at 13000 g for
10 min. One hundred microlitres of the supernatant was placed
in a chromacol vial, and 60 ml aliquots analysed by high perfor-
mance liquid chromatography (HPLC).
HPLC analysis
HPLC was carried out using a Spectra-Physics SP8700 solvent
delivery system, controlling a SP8750 pump, and a Gilson Model
231 sample injector with a 200 ml loop. Samples were injected
onto a Kingsorb S5 C18 column (25064.6 mm i.d.; Phenomenex)
with a guard column housing a C18 cartridge (463 mm i.d.).
Fluorescence detection was carried out with a Perkin Elmer LS
30 luminescence spectrometer, with excitation and emission wave-
lengths set at 345 and 405 nm respectively. Resveratrol, and its
metabolites, were separated using an isocratic mobile phase
composed of 25% acetonitrile and 75% 0.1 M formic acid (ammo-
nium salt; Sigma) at a ﬂow rate of 1.5 ml min
71, over 15 min.
Under these conditions the following retention times were
observed: resveratrol=12.45 min, piceatannol=6.91 min;
M1=7.68 min, M2=6.91 min, M3=6.30 min.
GC-MS analysis
Resveratrol and piceatannol trimethylsilyl (TMS) derivatives
(Res-TMS and Pic-TMS, respectively) were prepared as follows.
To a solution of the appropriate polyphenol (1 mg) in anhydrous
DMF (50 mL) was added SYLON-BTZ (Supelco; BSA:
TMSI:TMSCl, 3:3:2; 50 mL) and the mixture left for 30 min.
Derivatisation of CYP1B1 metabolism samples were carried out
as follows. An aqueous sample (9 ml) from the microsomal meta-
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Figure 1 Molecular structures of resveratrol, piceatannol, estradiol, and
4-hydroxyestradiol. (A) Shows the conversion of resveratrol to piceatannol
catalysed by CYP1B1. (B) Mapping of the phytoestrogen resveratrol onto
the steroid framework of estradiol. (C) Shows the CYP1B1 catalysed aro-
matic hydroxylation of estradiol to 4-hydroxyestradiol.
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Figure 2 HPLC traces using ﬂuorescence detection relating to the
metabolism studies. (A) Shows the presence of three metabolites M1,
M2, and M3 formed from the metabolism of resveratrol (Res) by CYP1B1
microsomes. (B) Shows the metabolism run without the NADPH cofactor.
(C) Shows the elution proﬁle of authentic piceatannol (Pic) containing a
small amount of resveratrol.
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(365 ml). The combined extracts were dried (Na2SO4) and
concentrated in vacuo. The residue was redissolved in anhydrous
DMF (50 mL) under dry nitrogen, SYLON-BTZ (50 mL) added,
and the mixture left for 1 h. The mixture was concentrated in
vacuo and stored until use in the dark at 7208C. Gas chromato-
graphy–mass spectrometry analysis was performed on a VG
70SEQ mass spectrometer in electron ionisation (EI) mode
(70 eV) coupled to a HP 5890 gas chromatograph with a PTE-5
30 m fused silica capillary column (Supelco). The injector tempera-
ture was 2808C. The derivatised samples of resveratrol and
piceatannol (Res-TMS and Pic-TMS) were separated by GC under
a variety of conditions. GC oven conditions of 808C for
1 min?2808C@158C min
71 gave retention times for Res-TMS
(m/z 444) of 17 min 34 s and Pic-TMS (m/z 532) of 19 min
21 s. GC oven conditions of 80ºC for 1 min?2808C@38C min
71
gave retention times for Res-TMS (m/z 444) of 60 min 0 s and
Pic-TMS (m/z 532) of 64 min 9 s.
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Figure 3 GC–MS studies on the derivatised metabolism sample. (A) Shows the GC–MS elution proﬁle of the derivatised metabolism sample, displayed
as a single ion chromatogram at m/z=532. (B) Shows the GC–MS elution proﬁle, displayed as a single ion chromatogram at m/z-532, for derivatised authen-
tic piceatannol (Pic-TMS; m/z=532). (C) Shows the mass spectrum of the metabolism sample peak that eluted at 64 min and 9 s. (D) Shows the mass
spectrum of derivatised authentic piceatannol (Pic-TMS).
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The metabolism of CYP1B1 was carried out using a microsomal
preparation of the human CYP1B1 enzyme (Crespi et al, 1997).
Using HPLC analysis with ﬂuorescence detection we observed the
formation of two major metabolites (M1 and M2) and one minor
metabolite M3 (Figure 2A). The major metabolite M2 has been
identiﬁed as piceatannol (3,4,3',5'-tetrahydroxystilbene). The other
metabolites M1 and M3 have not been conclusively identiﬁed
due to the unavailability of authentic standards. However we have
deduced that M1 is probably 3,4,5,4'-tetrahydroxystilbene which
results from 4-hydroxylation of the other aromatic ring, whilst
M3 is possibly the corresponding dihydroxylated metabolite
3,4,5,3',4'-pentahydroxystilbene. It is interesting to note here the
striking similarity in molecular structure of these two putative
metabolites to the structure of the highly potent anticancer agent
Combretastatin A4 (3-hydroxy-4,3',4',5'-tetramethoxystilbene)
(Dark et al, 1997). The other major metabolite M1 has been tenta-
tively assigned here as 3,4,5,4'-tetrahydroxystilbene, and this
stilbene has very recently been reported as an analogue of resvera-
trol that induces apoptosis in transformed cells, but not in their
normal counterparts (Lu et al, 2001). Thus formation of the meta-
bolite M1 could also make an important contribution to the
chemopreventive activity of resveratrol. Metabolism studies were
repeated with CYP1B1 obtained from a different source, using a
CYP1B1 transfected E. coli enzyme preparation (Li et al, 2000),
and this also gave the same metabolic proﬁle (data not shown).
Control experiments were carried out to validate these results by
repeating the metabolism experiments, but systematically omitting
a key component such as the substrate, the enzyme, or the essential
cytochrome P450 reductase cofactor NADPH, and in each of these
controls none of the metabolites were observed. The control
experiment where the metabolism of resveratrol was carried out
with the CYP1B1 microsomes, and only the NADPH cofactor
was omitted, is shown in Figure 2B for comparison. The metabolite
M2 was identiﬁed as piceatannol by HPLC coelution experiments
with authentic piceatannol, and this gave the same retention time
as M2. A spiking experiment was conducted where a small amount
of authentic piceatannol was added to the metabolism sample
following incubation, and HPLC analysis showed increased inten-
sity of the M2 peak without any separation of this peak. In
order to conclusively determine the identity of the metabolite
M2 as piceatannol, mass spectrometry studies were undertaken,
and a silylation derivatisation method was devised to enable sensi-
tive GC–MS analysis. In this method exhaustive silylation of the
metabolism sample was carried out so as to convert all hydroxlated
components to their fully silylated derivatives. Authentic silylated
materials were prepared for comparison and resveratrol was deriva-
tised to its tris(trimethylsilyl) derivative (m/z=444) and piceatannol
derivatised to its tetrakis(trimethylsilyl) derivative (m/z=532). The
metabolism sample was then subjected to the exhaustive silylation
procedure and analysed by GC–MS. Single ion monitoring at 532
was used to detect the GC elution proﬁle of any components
having a mass/charge ratio (m/z) of 532 corresponding to silylated
piceatannol. In this way a peak was observed in the metabolism
sample having a mass/charge ratio of 532 with an identical reten-
tion time as authentic silylated piceatannol. The GC conditions
were varied widely to ensure that the peak was free from any extra-
neous signals and upon varying the GC conditions coelution with
authentic silylated piceatannol was observed consistently. The most
demanding GC conditions gave a retention time for silylated picea-
tannol of 1 h 4 min and 9 s, and this peak was clearly seen in the
derivatised metabolism sample (Figure 3A,B). This peak from the
metabolism sample was then subjected to full mass spectral analy-
sis, by operating in full scan mode, and this spectrum is shown in
Figure 3C together with that of authentic silylated piceatannol in
Figure 3D for comparison, which conﬁrms its identity. Thus, using
both HPLC separation with ﬂuorescence detection and using GC
with mass spectral detection, we have veriﬁed that the metabolism
of resveratrol by CYP1B1 generates piceatannol as a major metabo-
lite.
Resveratrol has been implicated as a chemopreventive agent in
epidemiological studies, and a number of possible explanations
for this activity have been proposed (Adhami et al, 2001; Mollerup
et al, 2001; Wolter et al, 2001). In this pilot study we have demon-
strated that this activity could possibly be due to the CYP1B1
mediated bioactivation of resveratrol. In the light of this discovery
that CYP1B1 catalyses the conversion of a non-toxic dietary
component into a compound with anticancer properties, we
propose that the functional role of CYP1B1 is as a tumour suppres-
sor enzyme, or ‘rescue enzyme’. Previously it has been suggested
that CYP1B1 is present in tumours because it is the cause of
tumours, since it has been shown to activate procarcinogens into
carcinogens (Shimada et al, 1996; Kim et al, 1998). However this
does not adequately explain the cause of tumours since there are
many different mutagenic origins and oncogenic transformations
that result in various forms of cancer, and yet CYP1B1 appears
to be present in a wide variety of tumours irrespective of their
oncogenic origin (Murray et al, 1997). In the context of our
hypothesis that CYP1B1 is a tumour suppressor enzyme we need
to make the pertinent point that, with respect to carcinogenesis,
it does not matter if carcinogens are activated in cancer cells since
they are already cancerous. Indeed tumour cells exposed to acti-
vated carcinogens may well die from the mutagenic damage,
resulting in a cytotoxic effect (Shen et al, 1994). With respect to
our hypothesis another relevant observation is that CYP1B1 is
induced in skin cells on exposure to mutagenic UV light (Katiyar
et al, 2000). Our hypothesis may also explain the cancer preventa-
tive properties of other phytoestrogens (Adlercreutz, 1995) such as
ﬂavones, especially as it has recently been found that some ﬂavo-
noids are substrates for CYP1B1 (Doostdar et al, 2000).
In conclusion, the ﬁnding that resveratrol is converted into
piceatannol by CYP1B1 has a number of important implications.
Firstly, it provides a possible molecular mechanism for the cancer
preventative properties of resveratrol. Secondly, it shows that a
cancer preventative compound is converted into a compound with
known anticancer activity by an enzyme that is found in human
tumours. Thirdly, it provides supporting evidence for the hypoth-
esis that CYP1B1 is a tumour suppressor ‘rescue’ enzyme, acting
via natural prodrug bioactivation. Lastly, it validates the strategy
of developing CYP1B1 activated prodrugs for cancer therapy which
raises interesting opportunities for the treatment and prevention of
cancer.
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